Product Description: Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor CDK, with IC50s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively. Purvalanol B shows selectivity for CDK over a range of other protein kinases (IC50>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum[1][1].
Applications: Cancer-Kinase/protease
Formula: C20H25ClN6O3
References: [1]Gray NS, et, al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8./[2]Bullard KM, et, al. Effects of cyclin-dependent kinase inhibitor Purvalanol B application on protein expression and developmental progression in intra-erythrocytic Plasmodium falciparum parasites. Malar J. 2015 Apr 8;14:147.
CAS Number: 212844-54-7
Molecular Weight: 432.90
Compound Purity: 97.0
Research Area: Cancer; Infection
Solubility: DMSO : ≥ 40 mg/mL
Target: CDK;Parasite
Deutsch
English
